Traders Buy Large Volume of Put Options on Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw unusually large options trading on Tuesday. Traders bought 22,702 put options on the company. This is an increase of approximately 797% compared to the typical daily volume of 2,532 put options.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC boosted its position in Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after acquiring an additional 112,614 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after purchasing an additional 356,352 shares during the period. Geode Capital Management LLC grew its position in Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares in the last quarter. Bleakley Financial Group LLC increased its stake in Compass Therapeutics by 250.7% in the 4th quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock valued at $58,000 after buying an additional 28,589 shares during the period. Finally, Intech Investment Management LLC lifted its position in Compass Therapeutics by 218.7% in the 4th quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock worth $75,000 after buying an additional 35,632 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CMPX. Piper Sandler began coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price for the company. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Guggenheim began coverage on shares of Compass Therapeutics in a report on Monday, February 24th. They set a “buy” rating and a $12.00 target price for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Compass Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.38.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $2.24 on Wednesday. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $4.08. The firm’s 50 day simple moving average is $2.83 and its 200-day simple moving average is $2.11. The company has a market cap of $309.75 million, a P/E ratio of -6.05 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts expect that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.